CY1118151T1 - Νεα θεραπεια για την αμυλοειδωση που σχετιζεται με την τρανσθυρετινη - Google Patents
Νεα θεραπεια για την αμυλοειδωση που σχετιζεται με την τρανσθυρετινηInfo
- Publication number
- CY1118151T1 CY1118151T1 CY20161100934T CY161100934T CY1118151T1 CY 1118151 T1 CY1118151 T1 CY 1118151T1 CY 20161100934 T CY20161100934 T CY 20161100934T CY 161100934 T CY161100934 T CY 161100934T CY 1118151 T1 CY1118151 T1 CY 1118151T1
- Authority
- CY
- Cyprus
- Prior art keywords
- amyloidoidism
- inhibitor
- new transmission
- comt
- transmission treatment
- Prior art date
Links
- 230000005540 biological transmission Effects 0.000 title 1
- 102000006378 Catechol O-methyltransferase Human genes 0.000 abstract 4
- 108020002739 Catechol O-methyltransferase Proteins 0.000 abstract 4
- 108010071690 Prealbumin Proteins 0.000 abstract 2
- 102000009190 Transthyretin Human genes 0.000 abstract 2
- 206010002022 amyloidosis Diseases 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 abstract 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 abstract 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 abstract 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 abstract 1
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 229940016667 resveratrol Drugs 0.000 abstract 1
- 235000021283 resveratrol Nutrition 0.000 abstract 1
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Παρέχεται ένας αναστολέας της κατεχολο-Ο-μεθυλο-τρανσφεράσης (COMT) για να χρησιμοποιηθεί στην πρόληψη ή/και τη θεραπευτική αντιμετώπιση της σχετιζόμενης με την τρανσθυρετίνη αμυλοείδωσης. Παρέχεται επίσης ένας αναστολέας της κατεχολο-Ο-μεθυλο-τρανσφεράσης (COMT) για να χρησιμοποιηθεί στην πρόληψη ή/και τη θεραπευτική αντιμετώπιση της σχετιζόμενης με την τρανσθυρετίνη αμυλοείδωσης σε μία συνδυασμένη θεραπεία με έναν άλλον αναστολέα COMT, ένα παράγωγο βενζοξαζόλης, την ιωδοδιφλουνιζάλη, τη διφλουνιζάλη, τη ρεσβετατρόλη, το ταυροουρσο-δεοξυχολικό οξύ, τη δοξοκυκλίνη ή τη γαλλική επικατεχίνη-3.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11382326 | 2011-10-24 | ||
| PCT/EP2012/070945 WO2013060668A1 (en) | 2011-10-24 | 2012-10-23 | New therapy for transthyretin-associated amyloidosis |
| EP12778323.1A EP2770988B1 (en) | 2011-10-24 | 2012-10-23 | New therapy for transthyretin-associated amyloidosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118151T1 true CY1118151T1 (el) | 2017-06-28 |
Family
ID=47076222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161100934T CY1118151T1 (el) | 2011-10-24 | 2016-09-20 | Νεα θεραπεια για την αμυλοειδωση που σχετιζεται με την τρανσθυρετινη |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US9610270B2 (el) |
| EP (1) | EP2770988B1 (el) |
| JP (1) | JP6068484B2 (el) |
| KR (1) | KR102017354B1 (el) |
| CN (1) | CN103889407B (el) |
| AU (2) | AU2012327275B2 (el) |
| BR (1) | BR112014009322B1 (el) |
| CA (1) | CA2852808C (el) |
| CL (1) | CL2014000893A1 (el) |
| CY (1) | CY1118151T1 (el) |
| ES (1) | ES2593038T3 (el) |
| HK (1) | HK1198432A1 (el) |
| IL (1) | IL231907B (el) |
| MX (1) | MX347784B (el) |
| PL (1) | PL2770988T3 (el) |
| PT (1) | PT2770988T (el) |
| RU (2) | RU2747536C2 (el) |
| SG (2) | SG11201401215VA (el) |
| WO (1) | WO2013060668A1 (el) |
| ZA (1) | ZA201402546B (el) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2747536C2 (ru) * | 2011-10-24 | 2021-05-06 | Сом Инновэйшн Биотек, С.Л. | Новая терапия транстиретин-ассоциированного амилоидоза |
| KR102631505B1 (ko) * | 2014-08-29 | 2024-02-01 | 알닐람 파마슈티칼스 인코포레이티드 | 트랜스타이레틴(ttr) 매개 아밀로이드증의 치료 방법 |
| EP3275433A1 (en) * | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
| GB2585792A (en) * | 2018-03-12 | 2021-01-20 | Corino Therapeutics Inc | Combination of therapy for TTR amyloidosis |
| MX2021014682A (es) * | 2019-05-31 | 2022-04-06 | Plex Pharmaceuticals Inc | Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos. |
| CN114324693B (zh) * | 2022-01-14 | 2023-01-13 | 大连博源医学科技有限公司 | 一种血液中转甲状腺素蛋白(ttr)四聚体浓度测定的预处理方法和检测方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744368A (en) | 1993-11-04 | 1998-04-28 | Research Foundation Of State University Of New York | Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR) |
| AU5727798A (en) | 1996-12-23 | 1998-07-17 | Texas A & M University, The | Anti-amyloidogenic agents |
| FI20002044A0 (fi) * | 2000-09-15 | 2000-09-15 | Orion Yhtymae Oyj | Comt-entsyymiä estäviä naftaleenijohdannaisia |
| EP1372682B1 (en) | 2001-03-15 | 2012-05-02 | Proteotech Inc. | Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders |
| AU2003303666A1 (en) | 2002-01-29 | 2004-08-13 | Protemix Discovery Limited | Suppression of cytotoxic protein conformers |
| US20040175382A1 (en) | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| CA2555399A1 (en) | 2004-02-20 | 2005-09-01 | Novartis Ag | Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders |
| CN1921856A (zh) * | 2004-02-20 | 2007-02-28 | 诺瓦提斯公司 | 用于治疗神经变性疾病和认知障碍的dpp－iv抑制剂 |
| EP1768968A1 (en) | 2004-05-20 | 2007-04-04 | Foldrx Pharmaceuticals, Inc. | 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| DE602005019582D1 (de) | 2004-08-30 | 2010-04-08 | Seo Hong Yoo | Nervenschutzwirkung von aufgelöster udca bei einem fokalen ischämischen modell |
| GB2429645A (en) | 2006-03-10 | 2007-03-07 | Sekhsaria Chemicals Ltd | Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent |
| US20120016037A1 (en) | 2006-07-24 | 2012-01-19 | Frank Toppo | Method for prevention and treatment of Alzheimers |
| GB0718718D0 (en) | 2007-09-25 | 2007-11-07 | Pentraxin Therapeutics Ltd | Compound and use thereof |
| DE102010010572A1 (de) | 2010-03-08 | 2011-09-08 | Mahle International Gmbh | Trockenseparator |
| RU2747536C2 (ru) * | 2011-10-24 | 2021-05-06 | Сом Инновэйшн Биотек, С.Л. | Новая терапия транстиретин-ассоциированного амилоидоза |
-
2012
- 2012-10-23 RU RU2017119539A patent/RU2747536C2/ru active
- 2012-10-23 KR KR1020147010767A patent/KR102017354B1/ko active IP Right Grant
- 2012-10-23 SG SG11201401215VA patent/SG11201401215VA/en unknown
- 2012-10-23 WO PCT/EP2012/070945 patent/WO2013060668A1/en active Application Filing
- 2012-10-23 AU AU2012327275A patent/AU2012327275B2/en active Active
- 2012-10-23 JP JP2014536290A patent/JP6068484B2/ja active Active
- 2012-10-23 PL PL12778323T patent/PL2770988T3/pl unknown
- 2012-10-23 PT PT127783231T patent/PT2770988T/pt unknown
- 2012-10-23 CA CA2852808A patent/CA2852808C/en active Active
- 2012-10-23 EP EP12778323.1A patent/EP2770988B1/en active Active
- 2012-10-23 BR BR112014009322-9A patent/BR112014009322B1/pt active IP Right Grant
- 2012-10-23 CN CN201280051812.8A patent/CN103889407B/zh active Active
- 2012-10-23 ES ES12778323.1T patent/ES2593038T3/es active Active
- 2012-10-23 SG SG10201609933WA patent/SG10201609933WA/en unknown
- 2012-10-23 US US14/353,459 patent/US9610270B2/en active Active
- 2012-10-23 RU RU2014114930A patent/RU2623062C2/ru active
- 2012-10-23 MX MX2014004863A patent/MX347784B/es active IP Right Grant
-
2014
- 2014-04-03 IL IL231907A patent/IL231907B/en active IP Right Grant
- 2014-04-08 ZA ZA2014/02546A patent/ZA201402546B/en unknown
- 2014-04-09 CL CL2014000893A patent/CL2014000893A1/es unknown
- 2014-11-26 HK HK14111954.5A patent/HK1198432A1/xx unknown
-
2016
- 2016-09-20 CY CY20161100934T patent/CY1118151T1/el unknown
-
2017
- 2017-03-02 US US15/448,054 patent/US10045956B2/en active Active
- 2017-04-21 AU AU2017202670A patent/AU2017202670B2/en active Active
-
2018
- 2018-08-13 US US16/101,882 patent/US10449169B2/en active Active
-
2019
- 2019-09-12 US US16/569,055 patent/US10786473B2/en active Active
-
2020
- 2020-08-28 US US17/005,893 patent/US11564899B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118151T1 (el) | Νεα θεραπεια για την αμυλοειδωση που σχετιζεται με την τρανσθυρετινη | |
| CY1124298T1 (el) | Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet | |
| CY1121379T1 (el) | Πολυθεραπεια για την ισχαιμια | |
| CY1122186T1 (el) | Μεθοδοι θεραπειας καρκινου | |
| CY1122671T1 (el) | Θεραπευτικως δραστικες ενωσεις και οι μεθοδοι χρησεις αυτων | |
| NI201400109A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| CO2019005287A2 (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes | |
| CY1121041T1 (el) | Μεθοδοι αγωγης παιδιατρικων ασθενων με τη χρηση δεξμεδετομιδινης | |
| CY1120374T1 (el) | Ενεργοποιητες κινασων πυρουβικου για χρηση σε θεραπεια | |
| BR112019003914A2 (pt) | inibidores de processos metabólicos celulares | |
| NI201400110A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| CR9882A (es) | Milnacipran para el tratamiento a largo plazo del sindrome de fibromialgia | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| EA201790398A1 (ru) | Способы лечения заболевания печени | |
| CL2016001082A1 (es) | Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa | |
| CR20150571A (es) | Compuestos y composiciones terapéuticos | |
| BR112017007072A2 (pt) | compostos de triazolopiridina e métodos para o tratamento de fibrose cística | |
| CL2015002807A1 (es) | Terapia de combinación | |
| BR112015026021A2 (pt) | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer | |
| UY33476A (es) | Estimuladores de sgc | |
| GT201300320A (es) | Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer. | |
| NI201400111A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| CL2016000042A1 (es) | Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas. | |
| EA201490230A1 (ru) | Применение меченых ингибиторов hsp90 | |
| EA201590703A1 (ru) | Ингибиторы mek при лечении вирусных заболеваний |